Defronzo Lab

Research focus

NIH R01 · 2025

SGLT2 Inhibitors, Ketogenesis, and Ketoacidosis

PROJECT SUMMARY/ABSTRACT Sodium-glucose cotransport inhibitors (SGLT2i) lower the plasma glucose concentration by promoting glucosuria and have been shown to be effective in preventing cardiovascular events, including heart failure, and in slowing the progression of chronic kidney disease in diabetic and nondiabetic individuals. However, the uptake of the SGLT2i, especially in the general medical community but also by cardiologists and nephrologists, has been retarded by the development of diabetic ketoacidosis. Although uncommon in T2DM, DKA occurs in 3-5% of T1DM individuals treated with SGLT2i and primarily for this reason the SGLT2i have not been approved by FDA for use in T1DM…

From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.